Literature DB >> 11761441

A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells.

I Saeterdal1, M K Gjertsen, P Straten, J A Eriksen, G Gaudernack.   

Abstract

Microsatellite instability (MSI) is recognised as genome-wide alterations in repetitive DNA sequences caused by defects in the DNA mismatch repair machinery. Such mutation patterns have been found in almost all analysed malignancies from patients with hereditary non-polyposis colorectal cancer, and in approximately 15% of sporadic colorectal cancers. In cancers with the MSI phenotype, microsatellite-like sequences in coding regions of various cancer-related genes, including transforming growth factor beta receptor type II (TGF betaRII), are targets for mutations. The TGF betaRII gene harbours a 10-bp polyadenine tract, and mutations within this region are found in 90% of colorectal cancers with MSI. The frameshift mutations result in new amino acid sequences in the C-terminal part of the proteins, prematurely terminating where a novel stop codon appears. In this study we have defined new cytotoxic T lymphocyte (CTL) epitope (RLSSCVPVA), carrying a good HLA-A*0201 binding motif, and resulting from the most common frameshift mutation in TGF betaRII. A CTL line and several CTL clones were generated from an HLA-A2+ normal donor by repeated stimulation of T cells with dendritic cells pulsed with the peptide. One of the CTL clones was able to kill an HLA-A2+ colon cancer cell line harbouring mutant TGF betaRII. This epitope may be a valuable component in cancer vaccines directed at MSI-positive carcinomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11761441     DOI: 10.1007/s002620100222

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

1.  Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer.

Authors:  Fabian Echterdiek; Jonas Janikovits; Laura Staffa; Meike Müller; Bernd Lahrmann; Monika Frühschütz; Benjamin Hartog; Nina Nelius; Axel Benner; Mirjam Tariverdian; Magnus von Knebel Doeberitz; Niels Grabe; Matthias Kloor
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

Review 2.  Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors.

Authors:  Vid Leko; Steven A Rosenberg
Journal:  Cancer Cell       Date:  2020-08-20       Impact factor: 31.743

3.  Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection.

Authors:  Anna Maria Chiaravalli; Maddalena Feltri; Valentina Bertolini; Elena Bagnoli; Daniela Furlan; Roberta Cerutti; Raffaele Novario; Carlo Capella
Journal:  Virchows Arch       Date:  2005-10-27       Impact factor: 4.064

Review 4.  RNA vaccines in cancer treatment.

Authors:  Anita Bringmann; Stefanie Andrea Erika Held; Annkristin Heine; Peter Brossart
Journal:  J Biomed Biotechnol       Date:  2010-06-01

5.  Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO).

Authors:  Michael Linnebacher; Anne Wienck; Inga Boeck; Ernst Klar
Journal:  J Biomed Biotechnol       Date:  2010-03-18

6.  Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology.

Authors:  Renzo G DiNatale; A Ari Hakimi; Timothy A Chan
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

7.  Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene.

Authors:  Eva Ripberger; Michael Linnebacher; Yvette Schwitalle; Johannes Gebert; Magnus von Knebel Doeberitz
Journal:  J Clin Immunol       Date:  2003-09       Impact factor: 8.317

Review 8.  Colorectal cancer and immunity: what we know and perspectives.

Authors:  Simon Pernot; Magali Terme; Thibault Voron; Orianne Colussi; Elie Marcheteau; Eric Tartour; Julien Taieb
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

Review 9.  Alternative tumour-specific antigens.

Authors:  Christof C Smith; Sara R Selitsky; Shengjie Chai; Paul M Armistead; Benjamin G Vincent; Jonathan S Serody
Journal:  Nat Rev Cancer       Date:  2019-07-05       Impact factor: 60.716

Review 10.  Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.

Authors:  Dionisia Quiroga; H Kim Lyerly; Michael A Morse
Journal:  Curr Treat Options Oncol       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.